- Home
- CODX vs APRE Comparison
CODX vs APRE Comparison
Compare CODX & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CODX
- APRE
- Stock Information
- Founded
- CODX 2013
- APRE 2006
- Country
- CODX United States
- APRE United States
- Employees
- CODX N/A
- APRE N/A
- Industry
- CODX Medical/Dental Instruments
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CODX Health Care
- APRE Health Care
- Exchange
- CODX Nasdaq
- APRE Nasdaq
- Market Cap
- CODX 11.9M
- APRE 9.7M
- IPO Year
- CODX 2017
- APRE 2019
- Fundamental
- Price
- CODX $0.26
- APRE $1.80
- Analyst Decision
- CODX Buy
- APRE Strong Buy
- Analyst Count
- CODX 2
- APRE 2
- Target Price
- CODX $5.50
- APRE $15.50
- AVG Volume (30 Days)
- CODX 606.2K
- APRE 32.1K
- Earning Date
- CODX 05-08-2025
- APRE 05-14-2025
- Dividend Yield
- CODX N/A
- APRE N/A
- EPS Growth
- CODX N/A
- APRE N/A
- EPS
- CODX N/A
- APRE N/A
- Revenue
- CODX $3,497,583.00
- APRE $1,284,475.00
- Revenue This Year
- CODX N/A
- APRE N/A
- Revenue Next Year
- CODX $42.11
- APRE N/A
- P/E Ratio
- CODX N/A
- APRE N/A
- Revenue Growth
- CODX N/A
- APRE 33.27
- 52 Week Low
- CODX $0.23
- APRE $1.41
- 52 Week High
- CODX $2.23
- APRE $5.01
- Technical
- Relative Strength Index (RSI)
- CODX 38.53
- APRE 53.86
- Support Level
- CODX $0.23
- APRE $1.60
- Resistance Level
- CODX $0.34
- APRE $1.97
- Average True Range (ATR)
- CODX 0.06
- APRE 0.17
- MACD
- CODX -0.00
- APRE 0.02
- Stochastic Oscillator
- CODX 12.21
- APRE 62.50
About CODX Co-Diagnostics Inc.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.